← All trials
NCT02008721
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2014
- Primary completion
- Sep 1, 2016
- Completion date
- Dec 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 92
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Ludwig Maximilians UniversityLead sponsor
- German Center for Neurodegenerative Diseases (DZNE)Collaborator
- Deutsche Parkinson VereinigungCollaborator
- Deutsche Stiftung NeurologieCollaborator
- ParkinsonFonds Deutschland gGmbHCollaborator
- Ludwig Maximilians UniversityOverall official - principal investigator
- Ludwig Maximilians UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.